OPKO Health, Inc. (LON:0KCS)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 949.01M +20.3% |
| Revenue (ttm) | 492.68M +90.8% |
| Net Income | -111.52M |
| EPS | -0.15 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,707 |
| Open | 1.700 |
| Previous Close | 1.760 |
| Day's Range | 1.700 - 1.720 |
| 52-Week Range | 0.979 - 1.860 |
| Beta | 1.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About OPKO Health
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst... [Read more]
Financial Performance
In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.
Financial numbers in USD Financial StatementsNews
Opko Health reports Q3 EPS (7c), consensus (6c)
Reports Q3 revenue $65.4M vs. $56.4M last year. The company said, “Following the Board of Directors’ September 30, 2026 approval of a plan to sell substantially all remaining BioReference diagnostic…
Opko Health sees Q4 revenue $62M-$72M
The company said, “In light of the pending transaction with Labcorp, OPKO has withdrawn its previously issued guidance for services revenue and total costs and expenses due to uncertainty regarding…
Opko Health sees FY26 revenue $268M-$278M
The company said, “In light of the pending transaction with Labcorp, OPKO has withdrawn its previously issued guidance for services revenue and total costs and expenses due to uncertainty regarding…
OPKO Health Earnings Call Transcript: Q3 2026
Q3 continuing-operations revenue grew 16% YoY to $65.4M, while the planned Labcorp asset sale would provide ~$722M cash and complete the diagnostics exit. FY continuing-operations revenue guidance is $268M–$278M.
OPKO Health Earnings release: Q3 2026
OPKO Health released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
OPKO Health Quarterly report: Q3 2026
OPKO Health has published its Q3 2026 quarterly earnings report on November 4, 2026.
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended...
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the ...
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2...
Opko Health price target raised to $4 from $3 at Piper Sandler
Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Opko Health (OPK) to $4 from $3 and keeps an Overweight rating on the shares. The firm notes the…
Opko Health upgraded to Outperform from Market Perform at Barrington
Barrington upgraded Opko Health (OPK) to Outperform from Market Perform with a $2.25 price target after the company entered into an agreement to divest its remaining BioReference Health assets to…
Labcorp to acquire laboratory testing assets of Opko Health subsidiary
Labcorp (LH) and OPKO Health (OPK) have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction,…
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.
OPKO Health Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is shifting from diagnostics to therapeutics, highlighted by ModeX’s multi-specific antibody platform and a robust clinical pipeline. Strategic collaborations with Merck and Regeneron, strong capital position, and active shareholder returns support growth, with several clinical milestones expected in the next 12–18 months.
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established...
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and en...
Cocrystal Pharma announces $5M investment from Opko Health
Cocrystal Pharma (COCP) announced a $5M investment from Opko Health (OPK) as the company advances its lead norovirus program toward Phase 1b topline data later this year. Under the terms…
Cocrystal Pharma announces $5M private placement with Opko Health
Cocrystal Pharma (COCP) announced a $5M investment from OPKO Health (OPK), a longtime investor in the company. Under the terms of the agreement, Cocrystal sold 5,474,053 shares of its common…
Opko Health sees Q3 revenue $131M-$142M, consensus $134.65M
Sees Q3 total costs and expenses $180M-$190M, with R&D expenses projected at $34M-$38M.
Opko Health sees FY26 revenue $560M-$585M, consensus $536.88M
Sees FY26 total costs and expenses $710M-$740M.
Opko Health reports Q2 EPS (1c), one estimate (11c)
Reports Q2 revenue $163.5M, consensus $131.23M. Reports Q2 pharmaceutical revenue rose to $89M, driven by higher sales volumes in Spain and Mexico and $29.4M recognized from an amended license agreeme...
OPKO Health Earnings Call Transcript: Q2 2026
Q2 2026 saw improved profitability, strong cash reserves, and pipeline progress, with revenue rising to $163.6M and operating loss narrowing to $7M. Diagnostics and pharma segments both improved, while guidance for 2026 was raised on the back of robust product and partnership revenue.
OPKO Health Earnings release: Q2 2026
OPKO Health released its Q2 2026 earnings on July 27, 2026, summarizing the period's financial results.
OPKO Health Quarterly report: Q2 2026
OPKO Health has published its Q2 2026 quarterly earnings report on July 27, 2026.
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across estab...